Age and the neuromuscular blockading effects of cisatracurium.
暂无分享,去创建一个
[1] Jieying Gao,et al. High-performance liquid chromatography assay with programmed flow elution for cisatracurium in human plasma: application to pharmacokinetics in infants and children. , 2014, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[2] H. Sharifnia,et al. Cost analysis and safety comparison of Cisatracurium and Atracurium in patients undergoing general anesthesia. , 2013, European review for medical and pharmacological sciences.
[3] K. Lim,et al. The effect of low dose ketamine and priming of cisatracurium on the intubating condition and onset time of cisatracurium , 2012, Korean journal of anesthesiology.
[4] F. Varin,et al. Cisatracurium pharmacokinetics and pharmacodynamics during hypothermic cardiopulmonary bypass in infants and children , 2011, Paediatric anaesthesia.
[5] 李军,et al. The neuromuscular blocking effect of different doses of cisatracurium in children , 2007 .
[6] Hu Aiping,et al. Pharmacodynamics of Cisastracurium in Children at Different Age , 2007 .
[7] C. Launo,et al. Cisatracurium versus vecuronium: a comparative, double blind, randomized, multicenter study in adult patients under propofol/fentanyl/N2O anesthesia. , 2006, Minerva anestesiologica.
[8] U. Aypar,et al. Infusion and bolus administration of cisatracurium--effects on histamine release. , 2005, Middle East journal of anaesthesiology.
[9] T. Riedel,et al. [Cis-atracurium--an equivalent substitution for atracurium in pediatric anesthesia?]. , 2002, Anaesthesiologie und Reanimation.
[10] M. Crawford,et al. Dose–Response Relationship and Infusion Requirement of Cisatracurium Besylate in Infants and Children during Nitrous Oxide–Narcotic Anesthesia , 2001, Anesthesiology.
[11] F. Xue,et al. [Influences of age and gender on dose-response and recovery time-course of atracurium]. , 2001, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae.
[12] H. Yannan. Histamine release and hemodynamic changes caused by cisatracurium , 2001 .
[13] G. Bikhazi,et al. Pharmacodynamics and intubating conditions of cisatracurium in children during halothane and opioid anesthesia. , 2000, Journal of clinical anesthesia.
[14] S. Tibby,et al. Clinical validation of cardiac output measurements using femoral artery thermodilution with direct Fick in ventilated children and infants , 1997, Intensive Care Medicine.
[15] T. Taivainen,et al. Pharmacokinetics and pharmacokinetic-dynamic modelling of rocuronium in infants and children. , 1997, British journal of anaesthesia.
[16] C. Lien,et al. Importance of the Organ-Independent Elimination of Cisatracurium , 1996, Anesthesia and analgesia.
[17] L. Skovgaard,et al. Good Clinical Research Practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents , 1996, Acta anaesthesiologica Scandinavica.
[18] R. Welch,et al. The in vitro degradation of cisatracurium, the R, cis‐R′‐isomer of atracurium, in human and rat plasma , 1995, Clinical pharmacology and therapeutics.
[19] C. Lien,et al. The Cardiovascular Effects and Histamine‐releasing Properties of 51W89 in Patients Receiving Nitrous Oxide/Opioid/Barbiturate Anesthesia , 1995, Anesthesiology.
[20] T. Taivainen,et al. Pharmacodynamic effects of 51W89, an isomer of atracurium, in children during halothane anaesthesia. , 1995, British journal of anaesthesia.
[21] O. Meretoja,et al. Duration of action of vecuronium in infants and children anaesthetized without potent inhalation agents , 1989, Acta anaesthesiologica Scandinavica.